FindTrial
Sign In

Analysis of the C1-Esterase Inhibitor at patients with COVID-19 as a biomarker for the course of the disease

Analysis of the C1-Esterase Inhibitor at patients with COVID-19 as a biomarker for the course of the disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00021440
Enrollment
50
Registered
2021-01-28
Start date
2020-04-17
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Group 1: positive PCR SARS-CoV-2 and treatment on intensive care unit: Blood withdrawal is performed singular after informed consent with the morning routine to measure the primary and secondary endpo

Sponsors

Universitätsklinikum Gießen und Marburg
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: positive PCR SARS-CoV-2; treatment on intensive care unit or home quarantine

Exclusion criteria

Exclusion criteria: age < 18 years

Design outcomes

Primary

MeasureTime frame
Concentration and activity of C1-Esterase-Inhibitor. Blood withdrawal is performed singular after informed consent with the morning routine.—

Secondary

MeasureTime frame
Concentration of des-Arg9-Bradykin Concentration of Angiotensin II Murray Score for ARDS Acute Kidney Injurie Dialysis Arrhythmia Troponin CRP PCT Lymphocytes GOT GPT LDH D-Dimere Fibrinogen The above-mentioned parameters are registered at the timepoint of blood withdrawal. The following parameters are captured after hospital discharge. 28 days lethality duration of stay on intensive care duration of stay at hospital duration of ventilation—

Countries

Germany

Contacts

Public ContactMichael Sander

Klinik für Anästhesiologie und operative Intensivmedizin

michael.sander@chiru.med.uni-giessen.de0641-98544401

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026